23 results
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
27 Sep 24
Quantum Biopharma Provides Corporate Update
8:09pm
the foregoing as it applies to such party represents a related-party transaction under Multilateral Instrument 61-101 - Protection of Minority Security … Holders in Special Transactions ("MI 61-101"), however the transaction is exempt from the formal valuation and minority shareholder approval
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
16 Sep 24
Quantum BioPharma Closes Private Placement Offering
7:27am
the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company has relied … on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
6 Sep 24
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Completes Debt Settlements
9:22pm
-101 due to the involvement of each of the Executives, who are officers of the Company, and would have required the Company to receive minority … related party transaction will be exempt from the formal valuation requirement and minority shareholder approval requirements of MI 61-101 based
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
26 Aug 24
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
6:18am
transaction”, as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Shareholders in Special Transactions (“MI 61-101”) due … to the involvement of each of the Executives, who are officers of the Company, and would require the Company to receive minority shareholder approval
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
15 Aug 24
Current report (foreign)
7:07am
by such insiders is considered a “related-party transaction” within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders … in Special Transactions (“MI 61-101”). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements
6-K
EX-99.1
e7bkht fwq3
12 Aug 24
FSD Pharma Announces Share Consolidation and Name Change
6:03am
6-K
EX-99.1
p4xo6b 4eh4bti86qmu
8 Jul 24
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
5:16pm
6-K
EX-99.2
6x7c0g6t1d1r2ttph wh
8 Jul 24
Amended and Restated Material Change Report
3:20pm
6-K
EX-99.1
0o3au7jc8as kjelr
8 Jul 24
Amended and Restated Material Change Report
3:20pm
424B5
a1cuhg bs3
16 Feb 24
Prospectus supplement for primary offering
6:36pm
F-3
gc5 dkcevn8
22 Dec 23
Shelf registration (foreign)
6:49pm
6-K/A
EX-99.1
rhe4h2oi6g2uufw4o
18 Dec 23
Material Change Report
12:31pm
6-K
EX-99.1
rxtvg1fraozds
5 Dec 23
FSD Pharma Inc. Announces Closing of Private Placement
10:33am
6-K
EX-99.1
m5i0ki883vcn85zuf
6 Nov 23
Current report (foreign)
6:36pm
6-K
EX-99.2
mg5t9tbgn6s3560
25 Aug 23
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a
4:18pm
6-K
EX-99.1
163n92l 2x
27 Sep 21
Material Change Report
12:00am
6-K
EX-99.2
xm9b3 qj6p
31 Aug 21
Material Change Report
2:06pm
6-K
EX-99.1
rnsrf
25 Aug 21
Acquisition Advances Company’s Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis
9:00am